dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Guilarte Clavero, Mar |
dc.contributor.author | Baeza, María Luisa |
dc.contributor.author | Cabañas, Rosario |
dc.contributor.author | Hernández, María Dolores |
dc.contributor.author | Ibañez, Ethel |
dc.contributor.author | Sala Cunill, Anna |
dc.date.accessioned | 2022-06-16T07:25:31Z |
dc.date.available | 2022-06-16T07:25:31Z |
dc.date.issued | 2021-12-29 |
dc.identifier.citation | Guilarte M, Sala-Cunill A, Baeza ML, Cabañas R, Hernández MD, Ibañez E, et al. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain. Allergy, Asthma Clin Immunol. 2021 Dec 29;17:137. |
dc.identifier.issn | 1710-1492 |
dc.identifier.uri | https://hdl.handle.net/11351/7700 |
dc.description | Bradicinina; Angioedema hereditari; Icatibant |
dc.description.sponsorship | The Icatibant Outcome Survey is funded and supported by Shire International GmbH, a Takeda company, Zurich, Switzerland. Under direction of the authors, Alpa Parmar, PhD, CMPP, Latoya M. Mitchell, PhD, CMPP, and Sophia Shumyatsky, PharmD, CMPP, employees of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, and copyediting also was provided by Excel Medical Affairs. Takeda Development Center Americas, Inc. provided funding to Excel Medical Affairs, provided funding to Excel Medical Affairs for support in editing this manuscript. The interpretation of the data was made by the authors independently. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Allergy, Asthma & Clinical Immunology;17 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Malalties congènites - Tractament |
dc.subject | Inflamació |
dc.subject | Proteïna C - Deficiència |
dc.subject.mesh | Angioedemas, Hereditary |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Surveys and Questionnaires |
dc.subject.mesh | Time-to-Treatment |
dc.title | Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13223-021-00641-3 |
dc.subject.decs | angioedemas hereditarios |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | encuestas y cuestionarios |
dc.subject.decs | tiempo hasta el tratamiento |
dc.relation.publishversion | https://doi.org/10.1186/s13223-021-00641-3 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Guilarte M, Sala-Cunill A] Secció d’Al•lèrgia, Servei de Medicina, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Research Network on Allergy (National Allergy Network ARADyAL: Asma, Reacciones Adversas y Alérgicas), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Baeza ML] Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Biomedical Research Network on Rare Diseases, CIBERER-U761, Gregorio Marañón Health Research Institute, Madrid, Spain. [Cabañas R] Allergy Department, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPaz), Madrid, Spain. Biomedical Research Network on Rare Diseases, CIBERER-U754, Madrid, Spain. [Hernández MD, Ibañez E] Allergy Department, IIS-Hospital Universitari I Politècnic La Fe, Valencia, Spain |
dc.identifier.pmid | 34965883 |
dc.identifier.wos | 000736714300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |